113 related articles for article (PubMed ID: 37632908)
1. The Importance of Gender-Neutral Terminology in Risk Evaluation and Mitigation Strategy Programs: A Call to Action.
Burnette C; Smithy W; Strock D; Sivesind TE; Dellavalle R
JMIR Dermatol; 2023 Jun; 6():e45329. PubMed ID: 37632908
[TBL] [Abstract][Full Text] [Related]
2. Contraceptive counseling for iPLEDGE and its burden on dermatologists.
Owens KE; Jiang SW; Nicholas MW
Arch Dermatol Res; 2024 May; 316(6):287. PubMed ID: 38805059
[TBL] [Abstract][Full Text] [Related]
3. Patient Access in Restrictive Risk Management Programs: The Case of iPLEDGE.
Kerr KW; Wosinska ME
Ther Innov Regul Sci; 2017 Jan; 51(1):16-23. PubMed ID: 30235995
[TBL] [Abstract][Full Text] [Related]
4. Removal of Isotretinoin Gender-Based Guidelines: Inclusivity Takes Precedence.
Nanda S
Cutis; 2022 Mar; 109(3):E18-E20. PubMed ID: 35659135
[TBL] [Abstract][Full Text] [Related]
5. iPLEDGE Must Abstain from Abstinence.
Lowery K; Rosen T; Malek J
J Clin Aesthet Dermatol; 2020 Jun; 13(6):54-56. PubMed ID: 32884622
[TBL] [Abstract][Full Text] [Related]
6. Prescribing isotretinoin for transgender youth: A pledge for more inclusive care.
Boos MD; Ginsberg BA; Peebles JK
Pediatr Dermatol; 2019 Jan; 36(1):169-171. PubMed ID: 30318854
[TBL] [Abstract][Full Text] [Related]
7. Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era.
Charrow A; Xia FD; Lu J; Waul M; Joyce C; Mostaghimi A
PLoS One; 2019; 14(3):e0210445. PubMed ID: 30913210
[TBL] [Abstract][Full Text] [Related]
8. A Call for Gender Identity Data Collection in iPLEDGE and Increasing the Number of Isotretinoin Prescribers Among Transgender Health Providers.
Singer S; Keuroghlian AS
LGBT Health; 2020 Jul; 7(5):216-219. PubMed ID: 32456537
[TBL] [Abstract][Full Text] [Related]
9. Administrative Burden of iPLEDGE Deters Isotretinoin Prescriptions: Results From a Survey of Dermatologists.
Lee G; Wolf JR; Somers KE
Cutis; 2022 Jul; 110(1):44-47. PubMed ID: 36179224
[TBL] [Abstract][Full Text] [Related]
10. Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States.
Pinheiro SP; Kang EM; Kim CY; Governale LA; Zhou EH; Hammad TA
Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1251-7. PubMed ID: 23913625
[TBL] [Abstract][Full Text] [Related]
11. Readability of iPledge materials for isotretinoin education in English and Spanish.
DeMeo D; Reddy HA; Cowden MP; Maytin AK; Carroll BT
Arch Dermatol Res; 2023 Sep; 315(7):2175-2178. PubMed ID: 36918437
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies.
Sarayani A; Albogami Y; Thai TN; Smolinski NE; Patel P; Wang Y; Nduaguba S; Rasmussen SA; Winterstein AG
Am J Obstet Gynecol; 2022 Aug; 227(2):263.e1-263.e38. PubMed ID: 35032444
[TBL] [Abstract][Full Text] [Related]
14. The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system.
Shin J; Cheetham TC; Wong L; Niu F; Kass E; Yoshinaga MA; Sorel M; McCombs JS; Sidney S
J Am Acad Dermatol; 2011 Dec; 65(6):1117-25. PubMed ID: 21565419
[TBL] [Abstract][Full Text] [Related]
15. Gender differences in isotretinoin prescriptions during the COVID-19 pandemic at a U.S. academic medical center.
Duan GY; Ruiz de Luzuriaga AM
Arch Dermatol Res; 2023 Apr; 315(3):643-645. PubMed ID: 36149480
[TBL] [Abstract][Full Text] [Related]
16. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
17. The future of iPLEDGE: We pledge for more inclusive access to isotretinoin.
Shah N; Kirkorian AY
Pediatr Dermatol; 2021 Nov; 38 Suppl 2():183-184. PubMed ID: 34184311
[No Abstract] [Full Text] [Related]
18. Emergency contraception in the iPLEDGE program: A cross-sectional survey of pediatric dermatology provider understanding and practice.
Smiley CE; Butt M; Zaenglein AL
Pediatr Dermatol; 2022 Sep; 39(5):727-730. PubMed ID: 35918308
[TBL] [Abstract][Full Text] [Related]
19. What is the best approach to reducing birth defects associated with isotretinoin?
Abroms L; Maibach E; Lyon-Daniel K; Feldman SR
PLoS Med; 2006 Nov; 3(11):e483. PubMed ID: 17121451
[TBL] [Abstract][Full Text] [Related]
20. Ignoring the elephant in the room-overregulated isotretinoin and unregulated dietary supplements in the United States.
Zamil DH; Paidisetty PS; Wang LK
Proc (Bayl Univ Med Cent); 2022; 35(6):892-893. PubMed ID: 36304632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
